Hans-Christian Kolberg, MD: Biosimilars and Patient Access

Video

Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the impact that biosimilars have made on patient access to therapy.

Transcript

In the developed countries, it’s very hard to say that it has improved; globally, it has improved. In the United States and in Germany, access to trastuzumab was not actually really a problem. In the developing countries, it definitely has improved. I know that from a hospital in China that I’m cooperating with.

Related Videos
Fran Gregory, PharmD, MBA
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Ryan Haumschild, PharmD, MS, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
andre harvin
Andre Harvin, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.